非小细胞肺癌患者PD-1通路抑制剂客观缓解率低与EGFR突变或ALK阳性有关

    EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer

    /

    返回文章
    返回